The bleeding disorders testing market was valued at $90.9 million in 2023, and is projected to reach $192.0 million by 2033, growing at a CAGR of 7.8% from 2024 to 2033.
Bleeding disorders are a group of medical conditions that impair the body’s ability to control blood clotting or coagulation, a process essential to prevent excessive bleeding after an injury. For diagnosing disorders that cause excessive bleeding or bruising, bleeding disorders testing are used to identify and evaluate conditions that affect the blood’s ability to clot. Early diagnosis through testing is essential for effective treatment and management, as it helps prevent potential complications, including joint damage, internal bleeding, and life-threatening hemorrhages.
The growth of the global bleeding disorders testing market alarming increase in prevalence of bleeding disorders and rise in awareness of early and accurate diagnostic testing. As per a 2022 study by Statista, approximately 208,957 individuals worldwide were suffering from hemophilia A and around 17,626 individuals had other platelet disorders. This emphasizes the urgent need for bleeding disorders testing to reduce the risk of these disorders and improve long-term outcomes. In addition, rise in trend of personalized medicine, which involves tailoring treatment plans as per individual's needs, fosters the market growth.
This is attributed to the fact that personalized treatment plans require specific diagnostic testing to identify the precise nature of a bleeding disorder. Furthermore, as healthcare systems in emerging economies improve, access to diagnostic testing for bleeding disorders is increasing, thus expanding the market. Moreover, increase in newborn screening programs to enable early diagnosis and treatment of bleeding disorders acts as a key deterrent factor of the global market. These programs aim to reduce complications from undiagnosed conditions and improve long-term health outcomes.
For instance, in 2018, the World Federation of Hemophilia developed a global registry, the WBDR, that allows hemophilia treatment centers to collect clinical data, monitor patient care, and identify gaps in management & treatment. However, high cost associated with genetic and molecular testing for bleeding disorders restrains the market growth. In addition, lack of awareness about bleeding disorders results in underdiagnosis and low demand for testing, which acts as a key deterrent factor of the global market.
On the contrary, development of advanced diagnostic tools, including genetic testing and point-of-care diagnostics, has improved the accuracy and speed of bleeding disorder detection, leading to higher adoption rates in healthcare settings. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global bleeding disorders testing industry is segmented into product, indication, end user, and region. On the basis of product, the market is bifurcated into reagents & consumables and instruments. Depending on indication, it is divided into hemophilia A, hemophilia B, Von Willebrand disease, and others. By end user, it is segregated into hospitals & clinics, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Depending on indication, the hemophilia A is anticipated to exhibit the highest growth during the forecast period.
By end user, the hospitals & clinics segment is projected to lead the bleeding disorders testing market in the near future.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the market during the forecast period.
Bleeding disorders are a group of medical conditions that impair the body’s ability to control blood clotting or coagulation, a process essential to prevent excessive bleeding after an injury. For diagnosing disorders that cause excessive bleeding or bruising, bleeding disorders testing are used to identify and evaluate conditions that affect the blood’s ability to clot. Early diagnosis through testing is essential for effective treatment and management, as it helps prevent potential complications, including joint damage, internal bleeding, and life-threatening hemorrhages.
The growth of the global bleeding disorders testing market alarming increase in prevalence of bleeding disorders and rise in awareness of early and accurate diagnostic testing. As per a 2022 study by Statista, approximately 208,957 individuals worldwide were suffering from hemophilia A and around 17,626 individuals had other platelet disorders. This emphasizes the urgent need for bleeding disorders testing to reduce the risk of these disorders and improve long-term outcomes. In addition, rise in trend of personalized medicine, which involves tailoring treatment plans as per individual's needs, fosters the market growth.
This is attributed to the fact that personalized treatment plans require specific diagnostic testing to identify the precise nature of a bleeding disorder. Furthermore, as healthcare systems in emerging economies improve, access to diagnostic testing for bleeding disorders is increasing, thus expanding the market. Moreover, increase in newborn screening programs to enable early diagnosis and treatment of bleeding disorders acts as a key deterrent factor of the global market. These programs aim to reduce complications from undiagnosed conditions and improve long-term health outcomes.
For instance, in 2018, the World Federation of Hemophilia developed a global registry, the WBDR, that allows hemophilia treatment centers to collect clinical data, monitor patient care, and identify gaps in management & treatment. However, high cost associated with genetic and molecular testing for bleeding disorders restrains the market growth. In addition, lack of awareness about bleeding disorders results in underdiagnosis and low demand for testing, which acts as a key deterrent factor of the global market.
On the contrary, development of advanced diagnostic tools, including genetic testing and point-of-care diagnostics, has improved the accuracy and speed of bleeding disorder detection, leading to higher adoption rates in healthcare settings. Such developments are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global bleeding disorders testing industry is segmented into product, indication, end user, and region. On the basis of product, the market is bifurcated into reagents & consumables and instruments. Depending on indication, it is divided into hemophilia A, hemophilia B, Von Willebrand disease, and others. By end user, it is segregated into hospitals & clinics, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of product, the reagent & consumables is expected to dominate the market from 2024 to 2033.Depending on indication, the hemophilia A is anticipated to exhibit the highest growth during the forecast period.
By end user, the hospitals & clinics segment is projected to lead the bleeding disorders testing market in the near future.
Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the market during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global bleeding disorders testing market include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., Grifols S.A., Danaher Corporation, Medtronic Plc, and Novo Nordisk A/S. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.Additional benefits you will get with this purchase are:
- Quarterly Update* (with the purchase of an enterprise license)
- 5 additional Company Profiles, pre- or post-purchase, as a free update.
- Free Updated Version (once released) with the purchase of an enterprise user license.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Product
- Reagents and Consumables
- Instruments
By Indication
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Others
By End User
- Hospitals and Clinics
- Diagnostic Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Grifols S.A.
- Danaher Corporation
- Medtronic plc
- Novo Nordisk A/S
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
CHAPTER 4: BLEEDING DISORDERS TESTING MARKET, BY PRODUCT
CHAPTER 5: BLEEDING DISORDERS TESTING MARKET, BY INDICATION
CHAPTER 6: BLEEDING DISORDERS TESTING MARKET, BY END USER
CHAPTER 7: BLEEDING DISORDERS TESTING MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
- Bio-Rad Laboratories, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Grifols S.A.
- Danaher Corporation
- Medtronic plc
- Novo Nordisk A/S
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 260 |
| Published | October 2024 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value ( USD | $ 90.9 million |
| Forecasted Market Value ( USD | $ 192 million |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
